|
CV Information
 PROFESOR MADYA DR. W. YUS HANIFF BIN W. ISA
| |
|---|---|
|
Grant's Name,"Project's Title" (Research Period)(Role)[Sponsorship]
| |
| 1 | , "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, VERSUS APIXABAN IN PARTICIPANTS WITH ATRIAL FIBRILLATION." (09.12.2024 - 09.12.2024) [ Jannsen ] - Source: HCMSv3 |
| 2 | , "OCEANIC AF" (05.04.2024 - 04.04.2025) [ Bayer ] - Source: HCMSv3 |
| 3 | , "A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CSL112 IN SUBJECTS WITH ACUTE CORONARY SYNDROME" (24.11.2022 - 31.12.2023) [ CSL Behring ] - Source: HCMSv3 |
| 4 | , "A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CSL112 IN SUBJECTS WITH ACUTE CORONARY SYNDROME" (24.11.2022 - 31.12.2023) [ CSL Behring ] - Source: HCMSv3 |
| 5 | , "MK-1242-035: A PIVOTAL PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE SGC STIMULATOR VERICIGUAT/MK-1242 IN ADULTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION" (25.04.2022 - 31.03.2025) [ Merk Sharp - Dohme (MSD) ] - Source: HCMSv3 |
| 6 | , "A STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) (MK-1242-001) (VICTORIA)" (20.09.2016 - 02.09.2019) [ Merck Sharp & Dohme Corp ] - Source: HCMSv3 |